Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors
Although many potent drugs have been used for cytokine storm, mortality is high for patients with coronavirus disease-2019 (COVID-19), which is followed up in the intensive care unit. Interferons (IFNs) are the major cytokines of the antiviral defense system released from many cell types. However, I...
Gespeichert in:
| Veröffentlicht in: | Indian journal of pharmacology 2021-05, Vol.53 (3), p.226-228 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 228 |
|---|---|
| container_issue | 3 |
| container_start_page | 226 |
| container_title | Indian journal of pharmacology |
| container_volume | 53 |
| creator | Cure, Erkan Kucuk, Adem Cure, Medine |
| description | Although many potent drugs have been used for cytokine storm, mortality is high for patients with coronavirus disease-2019 (COVID-19), which is followed up in the intensive care unit. Interferons (IFNs) are the major cytokines of the antiviral defense system released from many cell types. However, IFN-γ plays a key role in both primary and secondary cytokine storms. If the cytokine storm is not treated urgently, it will be fatal; therefore, it should be treated immediately. Anakinra, an interleukin-1 (IL-1) antagonist, tocilizumab, an IL-6 antagonist, and Janus kinase (JAK) inhibitors are successfully used in cytokine storm caused by COVID-19. However, sometimes, despite these treatments, the patient's clinical course does not improve. Emapalumab (Eb) is the human immunoglobulin G1 monoclonal antibody and is a potent and noncompetitive antagonist of IFN-γ. Eb can be life saving for cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and JAK inhibitors. |
| doi_str_mv | 10.4103/ijp.IJP_615_20 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8262416</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A666722372</galeid><sourcerecordid>A666722372</sourcerecordid><originalsourceid>FETCH-LOGICAL-c521m-b33467fb05846bf29812bdd3d597540cb58ec10cd50906f72ecef9b3135f503</originalsourceid><addsrcrecordid>eNp9ks1v0zAYxiMEYmVw5WyJC4em-CN24gvS1A3oNGlIIK6W4zit28QudtKq_F38gbxVB9PQQD746_c8tl8_Wfaa4FlBMHvn1tvZ4vqzEoQrip9kEyJllbOSk6fZBFPO8lIQdpa9SGmNYV5I8Tw7YwURUuJqkv2ca49sr7e6G3tdo9qizrUWJb1zfonaEFG0bdRmCPEwhbEZY7R-mCLtG7SNYRltSm5nkTkMYeM8SAHtkdFjsg2qD2h--21xmRM5RfuVMyvkEtgklwbtBzQEMNKgi3oKE-M69-N4kZP_tfZjQrCrk0XOr1ztwDy9zJ61ukv21V1_nn35cPV1_im_uf24mF_c5IZT0uc1Y4Uo2xrzqhB1S2VFaN00rOGy5AU2Na-sIdg0HEss2pJaY1tZM8J4yzE7z96fXLdj3dvGwKuj7tQ2ul7HgwraqYc73q3UMuxURQWFAoPB2zuDGL6PNg2qd8nYrtPehjEp-A3OZVHgCtA3f6HrMEYPjztSglNZEHpPLXVnlfNtgHPN0VRdCCFKSll5pPJHqKX1Fi4ZvG0dLD_gZ4_w0BrbO_M_gYkhJYjHn5oQrI6pVJBKdZ9KEFyeBPvQDTamTTfubVRQuo0P-3-oFKVCQTrV73SyX3VW7cs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2546529412</pqid></control><display><type>article</type><title>Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Cure, Erkan ; Kucuk, Adem ; Cure, Medine</creator><creatorcontrib>Cure, Erkan ; Kucuk, Adem ; Cure, Medine</creatorcontrib><description>Although many potent drugs have been used for cytokine storm, mortality is high for patients with coronavirus disease-2019 (COVID-19), which is followed up in the intensive care unit. Interferons (IFNs) are the major cytokines of the antiviral defense system released from many cell types. However, IFN-γ plays a key role in both primary and secondary cytokine storms. If the cytokine storm is not treated urgently, it will be fatal; therefore, it should be treated immediately. Anakinra, an interleukin-1 (IL-1) antagonist, tocilizumab, an IL-6 antagonist, and Janus kinase (JAK) inhibitors are successfully used in cytokine storm caused by COVID-19. However, sometimes, despite these treatments, the patient's clinical course does not improve. Emapalumab (Eb) is the human immunoglobulin G1 monoclonal antibody and is a potent and noncompetitive antagonist of IFN-γ. Eb can be life saving for cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and JAK inhibitors.</description><identifier>ISSN: 0253-7613</identifier><identifier>EISSN: 1998-3751</identifier><identifier>DOI: 10.4103/ijp.IJP_615_20</identifier><identifier>PMID: 34169908</identifier><language>eng</language><publisher>Pondicherry: Wolters Kluwer India Pvt. Ltd</publisher><subject>Care and treatment ; Causes of ; Coronaviruses ; COVID-19 ; Cytokine storm ; Epidemics ; Immunosuppressive agents ; India ; Lifesaving ; Monoclonal antibodies ; Short Communication</subject><ispartof>Indian journal of pharmacology, 2021-05, Vol.53 (3), p.226-228</ispartof><rights>COPYRIGHT 2021 Medknow Publications and Media Pvt. Ltd.</rights><rights>2021. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright: © 2021 Indian Journal of Pharmacology 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c521m-b33467fb05846bf29812bdd3d597540cb58ec10cd50906f72ecef9b3135f503</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262416/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262416/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids></links><search><creatorcontrib>Cure, Erkan</creatorcontrib><creatorcontrib>Kucuk, Adem</creatorcontrib><creatorcontrib>Cure, Medine</creatorcontrib><title>Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors</title><title>Indian journal of pharmacology</title><description>Although many potent drugs have been used for cytokine storm, mortality is high for patients with coronavirus disease-2019 (COVID-19), which is followed up in the intensive care unit. Interferons (IFNs) are the major cytokines of the antiviral defense system released from many cell types. However, IFN-γ plays a key role in both primary and secondary cytokine storms. If the cytokine storm is not treated urgently, it will be fatal; therefore, it should be treated immediately. Anakinra, an interleukin-1 (IL-1) antagonist, tocilizumab, an IL-6 antagonist, and Janus kinase (JAK) inhibitors are successfully used in cytokine storm caused by COVID-19. However, sometimes, despite these treatments, the patient's clinical course does not improve. Emapalumab (Eb) is the human immunoglobulin G1 monoclonal antibody and is a potent and noncompetitive antagonist of IFN-γ. Eb can be life saving for cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and JAK inhibitors.</description><subject>Care and treatment</subject><subject>Causes of</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Cytokine storm</subject><subject>Epidemics</subject><subject>Immunosuppressive agents</subject><subject>India</subject><subject>Lifesaving</subject><subject>Monoclonal antibodies</subject><subject>Short Communication</subject><issn>0253-7613</issn><issn>1998-3751</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9ks1v0zAYxiMEYmVw5WyJC4em-CN24gvS1A3oNGlIIK6W4zit28QudtKq_F38gbxVB9PQQD746_c8tl8_Wfaa4FlBMHvn1tvZ4vqzEoQrip9kEyJllbOSk6fZBFPO8lIQdpa9SGmNYV5I8Tw7YwURUuJqkv2ca49sr7e6G3tdo9qizrUWJb1zfonaEFG0bdRmCPEwhbEZY7R-mCLtG7SNYRltSm5nkTkMYeM8SAHtkdFjsg2qD2h--21xmRM5RfuVMyvkEtgklwbtBzQEMNKgi3oKE-M69-N4kZP_tfZjQrCrk0XOr1ztwDy9zJ61ukv21V1_nn35cPV1_im_uf24mF_c5IZT0uc1Y4Uo2xrzqhB1S2VFaN00rOGy5AU2Na-sIdg0HEss2pJaY1tZM8J4yzE7z96fXLdj3dvGwKuj7tQ2ul7HgwraqYc73q3UMuxURQWFAoPB2zuDGL6PNg2qd8nYrtPehjEp-A3OZVHgCtA3f6HrMEYPjztSglNZEHpPLXVnlfNtgHPN0VRdCCFKSll5pPJHqKX1Fi4ZvG0dLD_gZ4_w0BrbO_M_gYkhJYjHn5oQrI6pVJBKdZ9KEFyeBPvQDTamTTfubVRQuo0P-3-oFKVCQTrV73SyX3VW7cs</recordid><startdate>20210501</startdate><enddate>20210501</enddate><creator>Cure, Erkan</creator><creator>Kucuk, Adem</creator><creator>Cure, Medine</creator><general>Wolters Kluwer India Pvt. Ltd</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications & Media Pvt. Ltd</general><general>Wolters Kluwer - Medknow</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210501</creationdate><title>Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors</title><author>Cure, Erkan ; Kucuk, Adem ; Cure, Medine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c521m-b33467fb05846bf29812bdd3d597540cb58ec10cd50906f72ecef9b3135f503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Care and treatment</topic><topic>Causes of</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Cytokine storm</topic><topic>Epidemics</topic><topic>Immunosuppressive agents</topic><topic>India</topic><topic>Lifesaving</topic><topic>Monoclonal antibodies</topic><topic>Short Communication</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cure, Erkan</creatorcontrib><creatorcontrib>Kucuk, Adem</creatorcontrib><creatorcontrib>Cure, Medine</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Indian journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cure, Erkan</au><au>Kucuk, Adem</au><au>Cure, Medine</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors</atitle><jtitle>Indian journal of pharmacology</jtitle><date>2021-05-01</date><risdate>2021</risdate><volume>53</volume><issue>3</issue><spage>226</spage><epage>228</epage><pages>226-228</pages><issn>0253-7613</issn><eissn>1998-3751</eissn><abstract>Although many potent drugs have been used for cytokine storm, mortality is high for patients with coronavirus disease-2019 (COVID-19), which is followed up in the intensive care unit. Interferons (IFNs) are the major cytokines of the antiviral defense system released from many cell types. However, IFN-γ plays a key role in both primary and secondary cytokine storms. If the cytokine storm is not treated urgently, it will be fatal; therefore, it should be treated immediately. Anakinra, an interleukin-1 (IL-1) antagonist, tocilizumab, an IL-6 antagonist, and Janus kinase (JAK) inhibitors are successfully used in cytokine storm caused by COVID-19. However, sometimes, despite these treatments, the patient's clinical course does not improve. Emapalumab (Eb) is the human immunoglobulin G1 monoclonal antibody and is a potent and noncompetitive antagonist of IFN-γ. Eb can be life saving for cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and JAK inhibitors.</abstract><cop>Pondicherry</cop><pub>Wolters Kluwer India Pvt. Ltd</pub><pmid>34169908</pmid><doi>10.4103/ijp.IJP_615_20</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0253-7613 |
| ispartof | Indian journal of pharmacology, 2021-05, Vol.53 (3), p.226-228 |
| issn | 0253-7613 1998-3751 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8262416 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Care and treatment Causes of Coronaviruses COVID-19 Cytokine storm Epidemics Immunosuppressive agents India Lifesaving Monoclonal antibodies Short Communication |
| title | Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T18%3A04%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Can%20emapalumab%20be%20life%20saving%20for%20refractory,%20recurrent,%20and%20progressive%20cytokine%20storm%20caused%20by%20COVID-19,%20which%20is%20resistant%20to%20anakinra,%20tocilizumab,%20and%20Janus%20kinase%20inhibitors&rft.jtitle=Indian%20journal%20of%20pharmacology&rft.au=Cure,%20Erkan&rft.date=2021-05-01&rft.volume=53&rft.issue=3&rft.spage=226&rft.epage=228&rft.pages=226-228&rft.issn=0253-7613&rft.eissn=1998-3751&rft_id=info:doi/10.4103/ijp.IJP_615_20&rft_dat=%3Cgale_pubme%3EA666722372%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2546529412&rft_id=info:pmid/34169908&rft_galeid=A666722372&rfr_iscdi=true |